5 March 2013-Intervention of Nepal (LDC Group) at WTO Council for TRIPS: Request for an Extension of the Transitional Period
On Tuesday, 5 March 2013, the Ambassador of Nepal made the following intervention at the World Trade Organization’s Council for TRIPS, on behalf of the LDC Group on agenda item 11, Request for an Extension of the Transitional Period under Article 66.1 of the TRIPS Agreement.
WTO Council for TRIPS Meeting, March 5-6, 2013
Agenda item 11 – Request for an Extension of the Transitional Period under Article 66.1 of the TRIPS AgreementPresentation of Request (IP/C/W/583) by Nepal on Behalf of LDCs Group
Mr. Chairman,
5 March 2013-WTO TRIPS Council-Intervention of India on LDC request for an extension to the transition period
On 5 March 2013, the Government of India made the following intervention at the TRIPS Council under agenda item 11, request for an extension of the transitional period under Article 66.1 of the TRIPS Agreement. In their intervention, India unequivocally supported the duly motivated requested submitted by Haiti on behalf of the LDC Group on 5 November 2012 (IP/C/W/583).
India asserted that the “no roll back provision” of the 2005 extension had no place in the TRIPS Agreement and noted that
5 March 2013-WTO TRIPS Council-Intervention of India on Intellectual Property and Innovation: Small and medium Sized Enterprises
On 5 March 2013, the Government of India delivered the following statement at the TRIPS Council on agenda item 13, Intellectual Property and Innovation: Small and Medium-Sized Enterprises, a standalone item tabled by Chile, Chinese Taipei, the Republic of Korea and the United States of America.
We thank the delegations of Chinese Taipei, Korea, the United States and others for tabling an agenda item on “Intellectual Property and Innovation: Small and medium Sized Enterprises” which we understand is a standalone item.India Intellectual Property Appeals Board (IPAB) upholds compulsory license on cancer drug in Bayer v Natco
As others have reported, the India Intellectual Property Appeals Board (IPAB) has upheld the compulsory license on the Bayer patents on the cancer drug sorafenib, sold under the trademark of Nexavar by Bayer.
KEI on Medicines Patent Pool license (and MoU) with ViiV Healthcare
KEI comment on the Medicines Patent Pool license and MoU with ViiV Healthcare
28 February 2013FYI: James Love (james.love@keionline.org, +1.202.361.3040), Krista Cox (krista.cox@keionline.org, +1.202.332.2670) or Thiru Balasubramaniam (thiru@keionline.org).
The 27 February 2013 agreements between the Medicines Patent Pool (MPP) and ViiV Healthcare, a joint venture of GlaxoSmithKline, Pfizer, and Shionogi will expand access to affordable pediatric formulas for HIV/AIDS.
26 February 2013: UNDP/UNAIDS support LDC request for an extension to the TRIPS transition period
On 26 February 2013, one week before the WTO TRIPS Council (5-6 March 2013) meets to consider the LDC Group’s request (IP/C/W/583) for an extension of the transitional period under Article 66.1 of the TRIPS Agreement, UNDP and Continue Reading
The US Department of Justice and USPTO call for compulsory licenses on thousands of “standards-essential” patents
On January 8, 2013, the US Department of Justice (DOJ) and the U.S. Patent and Trademark Office (PTO) issued a joint statement on “remedies for standards-essential patents subject to voluntary F/RAND commitments. (Copy of statement here). Continue Reading
KEI intervention to WIPO Standing Committee on the Law of Patents: patents and health
The following statement was delivered at the 19th session of the WIPO Standing Committee on the Law Of Patents (SCP) after presentations by the secretariats of WIPO, WHO and WTO on the trilateral report.
26 February 2013
TRIPS Council meeting (5-6 March 2013: LDC request for an extension to transition period and New Zealand plain packaging)
The following WTO airgram WTO/AIR/4075/REV.1 (22 February 2013) contains the agenda for the upcoming WTO Council for TRIPS meeting to be held in Geneva from Tuesday, 5 March 2013 to Wednesday, 6 March 2013. The March 2013 session of the TRIPS Council will discuss the LDC Group’s request (IP/C/W/583) for an extension of the transitional period under Article 66.1 of the TRIPS Agreement under agenda item 11. Continue Reading
October 2012: Chinese comments on future work of WIPO patent committee (L&Es, patent quality and patents and health)
On 17 October 2012, the State Intellectual Property Office of China submitted the following comments to the Electronic Forum of WIPO’s Standing Committee on the Law of Patents (SCP) in relation to the future work of the Committee. The written submission focused on: 1) Exceptions and Limitations to Patent Rights, 2. Quality of Patents and 3. Patents and Health. These points were encapsulated in China’s general intervention today.
[English translation by WIPO]
Continue Reading